CDK4/6抑制剂联合内分泌治疗对乳腺癌细胞miRNA表达水平的影响

目的:分析CDK4/6抑制剂联合内分泌药物对人乳腺癌细胞中相关miRNA表达水平的影响。方法:培养人乳腺癌细胞MDA-MB-231、SK-BR-3、MCF-7株，使用CDK4/6抑制剂帕布昔利布和内分泌药物阿那曲唑作用于人乳腺癌细胞，MTT法检测细胞增殖情况，BD流式细胞仪检测细胞凋亡和细胞周期情况，采用RT-PCR检测相关miRNA表达情况，Western blot 检测TNF-α、Survivin蛋白表达。结果:在药物作用12 h、24 h、48 h和72 h后的MDA-MB-231研究组、SK-BR-3研究组、MCF-7研究组细胞中miRNA-1321、miRNA-574-5p、miRNA-24-3p的表达水平均较对照组有所下降，而miRNA-1246、miRNA-494-3p、miRNA-29b-3p的表达水平有所升高；MDA-MB-231研究组、SK-BR-3研究组、MCF-7研究组细胞G0/G1期、S期的比例均较对照组细胞均有所升高，而G2/M期比例与对照组相比较均有所下降；MDA-MB-231研究组、SK-BR-3研究组、MCF-7研究组细胞中TNF-α及Survivin的表达水平均较对照组有所上升。结论:CDK4/6抑制剂联合内分泌药物可以调节人乳腺癌细胞中相关miRNA表达水平，从而抑制人乳腺癌细胞增殖。

Effect of CDK4/6 inhibitor combined with endocrine therapy on miRNA expression in breast cancer cells

Objective:To analyze the effect of CDK4/6 inhibitor combined with endocrine drugs on the related miRNA expression in human breast cancer cells.Methods:The human breast cancer cell lines MDA-MB-231，SK-BR-3 and MCF-7 were cultured and treated with palbociclib and anastrozole.MTT was used to detect cell proliferation.BD flow cytometry was used to detect apoptosis and cell cycle.RT-PCR was used to detect the expression of miRNA.Western blot was used to detect the expression of TNF-α and Survivin protein.Results:The expression levels of miRNA-1321，miRNA-574-5p，miRNA-24-3p in the MDA-MB-231 group，SK-BR-3 group and MCF-7 group at 12 h，24 h，48 h and 72 h after drug treatment were lower than control group.But the expression levels of miRNA-1246，miRNA-494-3p and miRNA-29b-3p were significantly higher than those in the control group.The proportions of cells in G0/G1 phase and S phase in MDA-MB-231 group，SK-BR-3 group and MCF-7 group were higher than that in control group，while the ratio of G2/M phase was decreased compared with that in control group.In MDA-MB-231，SK-BR-3 and MCF-7 group，the levels of TNF-α and Survivin were all higher than those in the control group.Conclusion:CDK4/6 inhibitor combined with endocrine drugs can regulate the expression of related miRNAs in human breast cancer cells，thereby inhibiting the proliferation of human breast cancer cells.